Maximizing clinical benefit with trastuzumab-Reference-Cited by-同舟云学术

Maximizing clinical benefit with trastuzumab

Published:2004-10 Issue: Volume:31 Page:35-44
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Bell Richard,Verma Shail,Untch Michael,Cameron David,Smith Ian

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference91 articles.

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

2. Trastuzumab (Herceptin) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC);Extra;Eur J Cancer,2004

3. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression;Konecny;Breast Cancer Res Treat,1999

4. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers;Pegram;Oncogene,1999

5. Combination chemotherapy for metastatic breast cancer;Nabholtz;Expert Rev Anticancer Ther,2002

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes;Journal of Breast Cancer;2011

2. Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer;American Journal of Clinical Oncology;2009-10

3. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine;The Oncologist;2009-04-01

4. HER2-Positive Breast Cancer: From Trastuzumab to Innovatory Anti-HER2 Strategies;Clinical Breast Cancer;2008-02

5. A review of the use of trastuzumab (Herceptin®) plus vinorelbine in metastatic breast cancer;Annals of Oncology;2007-07